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Summary
Oncogenic mutations in the small Ras GTPases KRas, HRas, or NRas render the encoded proteins
constitutively GTP-bound and active, which promote cancer [1]. Ras proteins share ~85% amino
acid identity [2], are activated by [3] and signal through [4] the same proteins, and can exhibit
functional redundancy [5][6]. Nevertheless, manipulating expression or activation of each isoform
yields different cellular responses [7–10] and tumorigenic phenotypes [11–13], even when
different ras genes are expressed from the same locus [6]. We now report a novel regulatory
mechanism hardwired into the very sequence of RAS genes that underlies how such similar
proteins impact tumorigenesis differently. Specifically, despite their high sequence similarity,
KRAS is poorly translated compared to HRAS due to enrichment in genomically
underrepresented, or rare, codons. Converting rare to common codons increased KRas expression
and tumorigenicity to mirror that of HRas. Furthermore, in a genome-wide survey similar gene
pairs with opposing codon bias were identified that not only manifested dichotomous protein
expression, but were also enriched in key signaling protein classes and pathways. Thus,
synonymous nucleotide differences affecting codon usage account for differences between HRas
and KRas expression and function, and may represent a broader regulation strategy in cell
signaling.
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Results
Oncogenic HRAS cDNA, when ectopically over-expressed in human cells consistently
produced twenty-fold more protein than the identically tagged oncogenic version of the
© 2012 Elsevier Inc. All rights reserved.
*Corresponding author, count004@mc.duke.edu.
§Equal contribution.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
NIH Public Access
Author Manuscript
Curr Biol. Author manuscript; available in PMC 2014 January 07.
Published in final edited form as:













major splice form (4B) of KRAS cDNA (termed KRAS), regardless of the method of
introducing DNA, cell type, epitope tag, promoter, exogenous UTRs, introns, mutation, or
membrane targeting (Figures 1A and S1A–H). To explore this difference further, KRAS*
was generated by fusing HRAS cDNA encoding the first 158 amino acids (mutated at nine
residues to match KRas) to KRAS cDNA encoding the terminal hypervariable 30 amino
acids (Figure S1I). KRAS* produced more KRas protein than KRAS, regardless of other
parameters, indicating KRAS nucleotide sequence limits protein expression. KRas* protein
was still expressed less than HRas protein (Figures 1A and S1A–C, E–G), whether this is a
consequence of the remaining KRAS sequence or due to other mechanisms remains to be
determined. Additionally, pERK and pAKT levels, measures of Ras effector activation, were
similar in cells expressing oncogenic HRas, KRas or KRas* (Figure S1G). Brief metabolic
labeling revealed higher KRas protein expression from KRAS* compared to KRAS (Figure
S1J), consistent with a translational etiology. Indeed, GST fused with KRAS cDNA (GST-
KRas) expressed little protein unless a STOP codon was inserted between the two (GST-
STOP-KRas), or if KRas protein was encoded from KRAS*, suggesting that ribosomes stall
upon entering KRAS mRNA (Figure 1B). Moreover, KRAS and KRAS* mRNA levels were
within two-fold of HRAS mRNA (Figure S1K), although KRAS was consistently the
lowest, perhaps reflecting no-go decay of stalled transcripts [14]. Thus, the nucleotide
sequence of KRAS message impedes translation.
Comparing the KRAS and HRAS sequence revealed that the third position of codons was
typically an A/T in KRAS, but G/C in HRAS. Based on human genome-wide analysis of the
relative frequencies that degenerate codons are used to encode for the same amino acid [15],
the A/T bias in KRAS corresponds to underrepresented (rare) codons (Figure 1C).
Consistent with rare codons limiting protein expression, KRas levels were increased when
translated from KRAS* mRNA (Figure 1A). Similarly, the bias toward rare codons was
conserved in mammalian and avian KRAS genes (Figure S1L), and equated with lower
expression compared to HRas in mammalian cells (Figure 1D). Moreover, zebrafish hras
and kras encoded by a mixture of rare and common codons exhibited comparable protein
expression at a level between that of mammalian HRas and KRas (Figures 1D and S1L).
Finally, progressively converting rare to common codons proportionally increased human
KRas protein expression, even upon changing only nine rare isoleucine and valine codons
scattered throughout KRAS to their common counterparts (Figures 1E and S1I). Thus, rare
codons limit KRAS translation.
To investigate this phenomenon at the endogenous level, HCT116 human cancer cells
(which have a KRASG13D allele) were infected with an AAV targeting vector [16] designed
to knock into KRAS exon 1 either opKRASG13D (oncogenic KRASG13D cDNA in which
130 rare codons were optimized to common codons), or uaKRASG13D (unaltered
KRASG13D cDNA). The resultant transcripts would be expressed from the endogenous
KRAS promoter and retain the 5’ UTR and first 17 coding nucleotides, minimizing effects
on translation initiation, but encode only the KRAS4B spliced product (Figure 2A).
Screening ~1,800 neomycin-resistant clones revealed four with opKRASG13D and two with
uaKRASG13D cDNA successfully knocked into one allele of the KRAS gene. Immunoblot
revealed poor expression of endogenous KRas in both the uaKRASG13D and control cell
lines exhibiting a random integration event, on par with the parental HCT116 cells.
Conversely, the opKRASG13D cell lines exhibited, on average, five-fold higher KRas protein
and two-fold higher KRAS mRNA levels (Figures 2B and S2A,B). This increase was lower
compared to the ectopic setting, consistent with overexpression systems magnifying the
effects of codon bias [17]. Thus, changing rare to common codons increases endogenous
KRas protein expression.
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Polysome profiling was performed to characterize relative ribosomal kinetics of endogenous
HRAS and endogenous untargeted KRAS mRNAs from HCT116 clone 5. Semi-quantitative
RT-PCR revealed that both transcripts accumulated in polysome fractions, although KRAS
occupied relatively heavier fractions despite nearly equal transcript length (Figure 2C),
indicating more dense packing of ribosomes. Pactamycin treatment to halt translation
initiation (Figure S2C) led to an accumulation of HRAS mRNA in lighter polysome and
ribosome-free fractions, indicative of ribosome translocation. As previously observed [18],
there was only a minimal shift of KRAS mRNA in the gradient, with the bulk of the
message retained in the heavy fractions (Figure 2C). These results were confirmed in HEK-
HT cells (Figure S2D). Polysome profiles of mRNA derived from the opKRASG13D
HCT116 clone 5 and uaKRASG13D HCT116 clone 1 were compared. Quantitative RT-PCR
analysis revealed that after pactamycin treatment (Figure S2C), opKRASG13D mRNA was
modestly shifted to lighter fractions relative to uaKRASG13D mRNA (Figure 2D), consistent
with the degree other transcripts are shifted upon alleviating ribosome stalling [19]. These
shifts were recapitulated in opKRASG13D HCT116 clone 4 (Figures S2C,E). Thus, rare
codons impede translation of endogenous KRAS mRNA.
The biological impact of codon bias in mammalian genes is largely unknown. However,
targeted replacement of codons in the Drosophila alcohol dehydrogenase gene with either
suboptimal [20] or optimal [21] codons can respectively decrease or increase enzyme
activity and alcohol tolerance, suggesting codon bias affects gene function in higher
eukaryotes. As oncogenic Ras can impart tumorigenic growth to cells, we used tumor
growth to assess the biological impact of altering codon bias of human KRAS. HEK-HT
cells, which require oncogenic HRas for tumor growth [22], were transduced with a vector
expressing no transgene, oncogenic HRasG12V, KRasG12V, or KRas*G12V (Figure 1A) and
assayed for tumor growth. KRasG12V, like vector cells, formed tumors with 90-fold smaller
masses and reduced kinetics compared to HRasG12V cells, an effect rescued by KRAS*G12V
(Figures 3A–C). Tumors that eventually formed 3 months later from KRasG12V cells
exhibited elevated KRas expression (Figure S3A). Tumorigenic growth of opKRASG13D
and uaKRASG13D knock-in clones in which targeted recombination occurred at the same
wild-type KRAS allele were compared. opKRASG13D clone 5 formed tumors with up to 30-
fold larger masses and increased kinetics compared to uaKRASG13D clones (Figure 3D–F),
although this was not as dramatic as observed in the ectopic setting. Tumors from
opKRASG13D cells retained differential KRas protein expression and, interestingly,
exhibited higher HRas expression (not shown). While altering rare codons may affect
protein folding and processing [17], there is a direct correlation between codon content,
protein expression, and tumorigenesis of ectopic and endogenous oncogenic KRAS.
To explore whether the differences in codon bias between RAS genes reflects a broader
regulation strategy, we performed a genome-wide survey to identify gene pairs with high
similarity and divergent codon usage (Table S1) using G-C content at synonymous sites
(GC3) as a proxy for rare codons [15]. Using KRAS and HRAS as a benchmark, the top 60
gene pairs had ≥80% amino acid identity and ≥1.8-fold difference in GC3 content (Figure
4A, Table S1). Twelve such cDNAs pairs were Myc epitope-tagged and expressed in human
cells. In every case, the gene enriched in rare codons expressed less protein. Changing rare
to common codons in the two genes CFL2 and ORMDL1 augmented protein expression to
that of CFL1 and ORMDL3 (Figure 4B). Thus, synonymous differences altering codon
usage influence expression of mammalian genes encoding similar proteins.
To assess the functional significance of this gene set, gene ontology analysis [23] was
performed on the top 150 gene pairs sharing high identity and large differences in GC3
content (Table S1). Strikingly, we found that this group of proteins was highly enriched for
proteins with purine-nucleotide binding or kinase activity. The enrichment of these proteins
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was ≥6 orders of magnitude more significant than enrichment of any other functional
category from the analysis of gene pairs from complementary combinations of identity and
GC3 content criteria (Figure 4C, Table S2). KEGG pathway analysis [24] was also
performed to determine if gene pairs reside in pathways. Insulin signaling, long-term
potentiation, and tight junction pathways, in particular, were significantly enriched for gene
pairs with high protein identity and differential codon usage (Figure 4D, Table S3). Thus,
the combination of two seemingly unrelated criteria — high protein identity and opposing
codon bias — identified unique functional classes of proteins as well as signaling pathways.
Discussion
While differences in KRas and HRas expression were previously reported in at least some
settings [25], the mechanism responsible and effects thereof remained unknown. Here we
present a novel regulatory strategy that has been hiding in plain sight: codon bias. Rare
codons throughout KRAS message impede translation and correspondingly protein, and to a
lesser extent, mRNA levels, and reduce oncogenic activity. This was surprising, as while
rare codons impede protein translation in heterologous expression systems [26, 27] and
common codon bias exists in highly expressed genes in bacteria and yeast [17], there are
few reports of it affecting expression of ectopic homologous transcripts [28–30], let alone
endogenous mammalian genes. Moreover, codon bias in mammals has been argued to be a
byproduct of genes residing within larger genomic regions of nucleotide bias (isochores)
that affect chomatin functions like meiotic recombination [31]. Furthermore, in genome-
wide translational assessment, sites of ribosome stalling did not correlate with presence of
rare codons [32]. Nevertheless, the effects of codon usage between RAS genes on protein
expression and function suggest that are indeed consequences resulting from synonymous
differences at the nucleotide level [20, 21, 33].
At face value, the finding that KRAS is an incredibly weak oncogene due to rare codon bias
seems at odds with this gene being the most commonly mutated RAS isoform in cancer [34].
However, untransformed cells are sensitive to oncogenic stress [35], and increasing levels of
transgenic HrasG12V result in progressively more growth arrested (senescent) cells and fewer
mammary lesions in mice [36]. Perhaps rare codons limit the expression of KRas to an ideal
range to initiate tumorigenesis — high enough to promote hyperplasia but low enough to
avoid excessive senescence. Indeed, IMR90 primary human fibroblasts expressing
KRAS*G12V or HRASG12V, but not KRASG12V, appeared to arrest with a senescent
morphology (Figure 3G and not shown). Interestingly, there is concordance between the
degree of rare codon bias and the mutation frequency amongst RAS family members (Figure
S3B,C). However, codon bias cannot alone account for these differences, as Hras cDNA
knocked into the Kras locus is mutated at a high frequency in a urethane model of lung
cancer [6]. Nevertheless, rare codons clearly crippled the oncogenic activity of KRAS,
which could be a barrier to malignant progression. In this regard, it has been hypothesized
that up-regulation of oncogenic KRas is a necessary intermediate step in tumor progression
after senescence escape [36]. Multiple mechanisms that may increase KRas expression
occur during cancer including KRAS gene amplification [37, 38], miRNA down-regulation
directly [39, 40] or indirectly by sequestration via the KRAS pseudogene [41], and a general
increase in tRNA levels [42, 43].
It was also striking that the divergent tumorigenesis phenotypes of two nearly identical
proteins were reconciled by altering codon usage. It is formally possible that changing
codon bias affected some other aspect of mRNA regulation, but the multitude of
complementary codon modification strategies implemented make this possibility less likely.
Codon usage might underlie functional differences between members in other protein
families with opposing codon bias. The enrichment of gene pairs with high amino acid
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sequence identity and divergent codon bias in signaling networks further suggests that codon
usage may impact entire signaling pathways. Indeed, differential regulation of functionally
redundant genes may add specificity to signal transduction [44], and there are situations in
which transcripts enriched in rare codons are preferentially translated in mammalian cells
[45]. Thus, codon bias is not only a novel mechanism regulating Ras isoforms, but may
reflect a broader regulatory strategy in signaling pathways.
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• Mammalian KRAS is enriched in rare codons that limit its expression.
• Changing rare to common codons increases ectopic and endogenous KRAS
expression.
• KRAS oncogenicity is limited by rare codons.
• Other gene pairs exhibit high sequence identity but opposing codon bias.
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Figure 1. Translation of KRAS is limited by rare codons
(A) Immunoblot of lysates isolated from human HEK-HT cells stably infected with the
retrovirus pBabepuro encoding the indicated N-terminal FLAG-epitope tagged oncogenic
(G12V) human Ras proteins (FLAG-RasG12V) with an αFLAG or αtubulin antibody. One
of three experiments. (B) Immunoblot of lystates isolated from HEK-HT cells transiently
transfected with the plasmid pCIneo encoding GST cDNA, a STOP codon where indicated,
and in frame the indicated FLAG-Ras cDNAs, with an αGST or αtubulin antibody. One of
three experiments. (C) Amino acid identity of HRas and KRas is shown in the middle bar.
Blue: identical amino acids. White: non-identical amino acids. Relative codon usage of
HRAS versus KRAS is shown in the upper and lower bars, respectively. Shade of red box:
relative rarity of the codon. Grey box: gaps in alignment or non-identical amino acids. (D)
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Immunoblot of lysates isolated from human HEK-HT cells stably infected with the
retrovirus pBabepuro encoding the indicated FLAG-Ras proteins isolated from the indicated
species with an αFLAG or αtubulin antibody. One of two experiments. (E) Immunoblot of
lysates isolated from human HEK-HT cells stably infected with the retrovirus pBabepuro
encoding FLAG-HRas, FLAG-KRas or FLAG-KRas* (in which the indicated rare codons
were progressively converted to the indicated common codons) with an αFLAG or αtubulin
antibody. One of two experiments. Detailed methodologies and regent descriptions are
provided in Supplemental Experimental Procedures. See also Figure S1.
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Figure 2. Rare codon bias limits endogenous KRAS translation
(A) Targeting strategy to knock into exon 1 the endogenous KRAS gene in human HCT116
colon cancer cells (ATCC) oncogenic KRASG13D cDNA in which 130 rare codons were
either optimized to common codons (opKRASG13D) or left unaltered (uaKRASG13D) by
AAV-based recombination [16]. (B) Immunoblot of lysates isolated from parental HCT116
cell line, stable clones with non-homologous vector integration, clones with homologous
integration of uaKRASG13D, and clones with homologous integration of opKRASG13D, with
an αKRas or αtubulin antibody. One of one to two experiments. (C) Semi-quantitative RT-
PCR using primers specific for HRAS and the non-targeted KRAS mRNA of the indicated
sedimentation fractions (relative positions of ribosome-free, ribosome subunits 40S, 60S and
Lampson et al. Page 11













80S and polysome fractions) isolated from HCT116 opKRASG13D clone 5 pre- (-) and post-
(+) pactamycin (pacta) treatment to halt translation initiation. (D) Quantitative RT-PCR
using primers specific for the KRASG13D knock-in mRNA of the indicated sedimentation
fractions isolated from HCT116 opKRASG13D clone 5 and uaKRASG13D clone 1 pre- and
post-pactamycin treatment to halt translation initiation. Detailed methodologies and regent
descriptions are provided in Supplemental Experimental Procedures. See also Figure S2.
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Figure 3. Rare codons limit oncogenic KRas-driven tumorigenesis
(A) Photograph and (B) mean weight ± SEM of tumors at endpoint, as well as (C) mean size
± SEM tumors over time derived from HEK-HT cells stably expressing: ● empty vector, ■
HRasG12V, ▲ KRasG12V, and ▼ KRas*G12V, n=4. (D) Photograph and (E) mean weight ±
SEM of tumors at endpoint, as well as (F) mean size ± SEM tumors over time derived from
HCT116 clones expressing ▲ opKRasG13D (clone 5), ■ uaKRasG13D (clone 1), or ▼
uaKRasG13D (clone 2), n=6. One of two experiments. ***P<0.001. (G) Change in IMR90
cell number over time following acute expression of the indicated FLAG-RasG12V
constructs. Left: Fold change in crystal violet absorbance at 590nm at the indicated time
points after cell plating is normalized to day 1 for each cell line. Relative cell number for
Lampson et al. Page 13













IMR90 cells expressing any of the oncogenic FLAG-Ras constructs was significantly lower
than empty vector control cells on days 8, 12, and 18 (P<0.01). Additionally, relative cell
numbers for both empty vector and FLAG-KRASG12V expressing cells were significantly
different from each other and FLAG-KRAS* G12V and FLAG-HRASG12V cells on days 12
and 18 (P<0.0001). Right: Crystal violet staining of intact cells at day 18, representative of
four replicates. One of one to two experiments. Detailed methodologies and regent
descriptions are provided in Supplemental Experimental Procedures. See also Figure S3.
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Figure 4. Gene pairs with divergent codon bias demonstrate correlating differences in expression
and cluster in unique signaling protein classes
(A) Percent amino acid identity versus log difference in CDS GC3 content of individual
protein pairs identified by BLAST alignment (grey points). Black points: gene pairs with
>80% identity and >1.8-fold difference in GC3 content. Blue cross: gene pair tested for
protein expression. Red cross: HRAS-KRAS gene pair. (B) Immunoblot of lysates isolated
from human 293 cells (ATCC) stably infected with the retrovirus pBabepuro encoding the
indicated N-terminal FLAG-epitope tagged cDNAs corresponding to human genes pairs of
high amino acid sequence identity that have a common (first) versus a rare (second) codon
bias, or the gene pair enriched in rare codons after rare codons were optizimized (op) to
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common codons, with an αFLAG or αtubulin antibody. One of one to two experiments.
Histogram comparing p values of (C) gene ontology categories or (D) KEGG signaling
pathways enriched in lists of gene pairs with high amino acid sequence identity and high
GC3 difference (green), high identity and low GC3 difference (pink), low identity and high
GC3 difference (purple), or lists of genes with high GC3 content (brown) or low GC3
content (aquamarine). Detailed methodologies and regent descriptions are provided in
Supplemental Experimental Procedures. See also Tables S1–3.
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